According to Future Market Insights research, during the projected period, the global catheter associated urinary tract infections treatment market is expected to grow at a CAGR of 3.0%. The market value is projected to increase from US$ 1.31 Billion in 2023 to US$ 1.76 Billion by 2033. The catheter associated urinary tract infections treatment market was valued at US$ 1.26 Billion at the end of 2022 and is anticipated to exhibit Y-o-Y growth of 3.9% in 2023.
Attributes | Details |
---|---|
Market Size (2023) | US$ 1.31 Billion |
Projected Market Value (2033) | US$ 1.76 Billion |
Global Market Growth Rate (2023 to 2033) | 3.0% CAGR |
Market Share of Top 5 Countries | 52.1% |
As assessed by Future Market Insights, among the drug type, quinolones held a market share of around 37.6% in the global market, in 2022. In 2022, the catheter associated urinary tract infections treatment market sales accounted for a revenue share of 72.3% in the global complicated UTI market, which was valued at around US$ 1.8 Billion.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global market recorded a historic CAGR of 4.1% in the last 5 years from 2017 to 2022.
Catheter associated urinary tract infections (CAUTIs) are common complications associated with use of the catheters. Elderly individuals are more susceptible to UTIs due to weakened immune systems, and urinary retentions. Moreover, individuals with compromised immune systems such as those with diabetics, or undergoing immunosuppressive therapy are at increased risk of UTIs.
These infections may also reoccur more frequently due to the body’s reduced ability to fight off the infection.
The growth of catheter associated urinary tract infections treatment market is due to the growing number of UTIs and recurrent UTIs. This has led to a higher demand for effective treatment choices.
The increasing prevalence of CAUTIs worldwide can be attributed to a variety of factors, including prolonged catheter use, inadequate catheter care and hygiene and other factors.
Patients may require catheterization for a prolonged time due to various medical conditions. Prolonged catheter use increases the opportunity for bacteria to colonise the urinary tract and cause infection. Proper maintenance and care of the urinary catheters are essential for the reduction of the infection.
Hence, the global catheter associated urinary tract infections treatment market is been driven by the high prevalence and incidence rate of the disease worldwide.
The demand for new treatment arises from the need to address antibiotic-resistant CAUTIs. As bacteria become resistant to traditional antibiotics, it becomes harder to treat these infections efficiently. This increases the risk of the implication and prolonged hospital stays for patients and adds a financial burden on the healthcare system due to the increased cost of treating drug-resistant infections.
The prevalence of antibiotic-resistant CAUTIs is a significant concern as it limits the effectiveness of traditional antibiotic therapy. Moreover, the development of new antibiotics is slow and costly, and the pipeline for novel antibiotics is relatively dry. Moreover, this can be a significant factor affecting the growth of the CAUTIs market.
The USA accounted for around 18.2% market share in the global market in 2022. The USA market’s growth is expected to rise at an overall CAGR of 2.2% over the forecast period.
Urinary tract infection is one of the most frequent infectious diseases caused by bacteria. A complicated urinary tract infection can affect anyone, regardless of gender or age, and they are caused by anatomical or functional abnormalities in the urinary system.
An increase in chronic illness such as diabetes, and kidney disease, such as renal failure and bladder cancer, is driving the usage of catheters and other drainage devices among patients and the increased use of indwelling use of urinary catheters is the attributing factor in the rise of complicated UTIs. Complicated UTIs are generally more challenging to treat compared to uncomplicated UTIs, as they are associated with more severe symptoms and have a higher risk of complication.
These are the major factors that help the market grow exponentially in the U.S., region.
The India market held around 10.2 % market share of the global market in 2022.
The large patient population in India is one of the reasons why the Indian market has a significant presence in the global catheter associated urinary tract infections treatment market.
With such a large population, the incidence and prevalence of CAUTIs are also higher.
Since CAUTI is a common healthcare-associated infection, the large patient population in India creates a high demand for CAUTIs treatment.
China held a market share of about 9.5% of the global market in 2022.
The Chinese government to improve healthcare outcomes and reduce healthcare-associated infections, including CAUTIs, has implemented several measures and programs.
The promotion of awareness and education regarding infection prevention measures is one significant initiative. The aim is to increase awareness among healthcare providers and patients about the risk associated with CAUTIs and the importance of preventing the infection.
The government provides training and education to healthcare providers to enhance their knowledge and skills in preventing CAUTIs. Additionally, they focus on this effort. In addition, supporting the adoption of infection prevention measures in healthcare facilities. China is in demand for the market of catheter-associated urinary tract infections.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The Quinolones sub-segment held around 37.6% share of the global market in 2022 within the drug type.
Quinolones have a broad-spectrum antimicrobial activity. In addition, Gram-negative organism commonly causes CAUTIs, and quinolones have demonstrated efficacy against these pathogens. In addition, quinolones have the ability to achieve high concentration in the urine, which is desirable for treating urinary tract infections.
Quinolones also have good penetration in the tissue of the urinary tract, including the bladder wall, renal parenchyma and prostate gland.
They are also available in both oral and intravenous formulations providing convenience and flexibility in the treatment of CAUTIs.
The Asymptomatic CAUTI (Bacteriuria) segment held around 58.9% share of the total market in 2022 within the indication type.
In comparison to symptomatic CAUTIs, asymptomatic CAUTIs are more common. Many patients with urinary catheters may not exhibit common infection symptoms, such as fever or pain, making it difficult to detect these infections without specialized testing.
The greater prevalence of asymptomatic CAUTIs contributes to its dominant position in the indication type segment.
Retail pharmacies hold a share of about 43.2% in 2022, within the global market.
Medication used in the treatment of CAUTIs is mainly distributed through retail pharmacies, which serve as the main distribution hubs. To ensure that patients have access to necessary antibiotics and other relevant drugs, they make sure that these medications are available.
In retail settings, pharmacists and pharmacy staff offer education and counselling to patients about the correct use of medication for CAUTIs. These are the services provided by them. Retail pharmacies offer a variety of over-the-counter products that can assist in managing CAUTIs in addition to the prescribed medication.
The treatment market for catheter-associated urinary tract infections treatment is competitive. In addition to expanding their presence in emerging markets through new partnerships and merger acquisitions, market leaders are concentrating on the introduction of technologically advanced products. The competitive environment includes an analysis of a handful of global and local corporations that control the majority of the market share. In addition to acquisitions, mergers, and partnerships with key market participants.
Some key instances of development include:
Similarly, the team at Future Market Insights has tracked recent developments related to companies in the catheter associated urinary tract infections treatment market, which are available in the full report.
Attribute | Details |
---|---|
Forecast Period | 2023 to 2033 |
Historical Data Available for | 2017 to 2022 |
Market Analysis | USD Million for Value |
Key Regions Covered | North America, Latin America, Europe, East Asia, South Asia, Oceania, Middle East and Africa. |
Key Countries Covered | USA, Canada, Brazil, Argentina, Mexico, Germany, France, UK, Italy, Spain, Russia, BENELUX, India, Thailand, Malaysia, Indonesia, China, Japan, South Korea, Australia, New Zealand, Türkiye, GCC Countries, Northern Africa, and South Africa |
Key Market Segments Covered | Drug Type, Indication, Distribution Channel and Region |
Key Companies Covered |
|
Report Coverage | Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives |
Customization & Pricing | Available upon Request |
The market is expected to be valued at US$ 1.31 billion in 2023.
AstraZeneca, Bayer AG, and Sanofi are the key market players.
Increased prevalence of chronic illnesses like diabetes drives catheter usage.
Retail pharmacies hold a share of about 43.2% in 2022.
The market is estimated to reach US$ 1.76 billion by 2033.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions and Exclusions 3. Key Market Trends 3.1. Key Trends Impacting the Market 3.2. Product Innovation / Development Trends 4. Value Added Insights 4.1. Product Adoption Analysis 4.2. Product USP Analysis 4.3. Pipeline Analysis 4.4. Regulatory Landscape, By Country 4.5. UTI Antibiotic Treatment Cycle 4.6. PESTLE Analysis 4.7. Porter’s Analysis 5. Market Background 5.1. Macro-Economic Factors 5.1.1. Global Pharmaceutical Outlook 5.1.2. Global Healthcare Expenditure 5.1.3. Global R&D Expenditure 5.1.4. Global Complicated UTI Market Outlook (Parent Market Outlook) 5.2. Forecast Factors - Relevance & Impact 5.2.1. Technological Advancements 5.2.2. Top Companies Historical Growth 5.2.3. Entry of Top Companies 5.2.4. Prevalence of CAUTIs 5.2.5. Focus on Infection Prevention 5.2.6. Aging Population and Healthcare Demographics 5.2.7. Regulatory Policies and Guidelines 5.2.8. Technological Advancements and Innovation 5.3. Market Dynamics 5.3.1. Drivers 5.3.2. Restraints 5.3.3. Opportunity Analysis 6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 6.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 6.2.1. Y-o-Y Growth Trend Analysis 6.2.2. Absolute $ Opportunity Analysis 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic 7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Type 7.1. Introduction / Key Findings 7.2. Historical Market Size (US$ Million) Trends Analysis By Drug Type, 2017 to 2022 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Type, 2023 to 2033 7.3.1. Penicillin & Combinations 7.3.1.1. Amoxicillin 7.3.1.2. Amoxicillin+ Clavulanate Potassium 7.3.1.3. Others 7.3.2. Quinolones 7.3.2.1. Ciprofloxacin 7.3.2.2. Levofloxacin 7.3.2.3. Nalidixic acid 7.3.2.4. Norfloxacin 7.3.2.5. Others 7.3.3. Cephalosporin 7.3.3.1. Ceftriaxone 7.3.3.2. Cefuroxime 7.3.3.3. Cefixime 7.3.3.4. Cephalexin 7.3.4. Aminoglycoside Antibiotics 7.3.4.1. Amikacin 7.3.4.2. Gentamicin 7.3.5. Sulphonamides (Sulfamethoxazole +Trimethoprim) 7.3.6. Azoles and Amphotericin B 7.3.7. Tetracycline (Doxycycline) 7.3.8. Nitrofurans (Nitrofurantoin) 7.3.9. Other 7.4. Market Attractiveness Analysis By Drug Type 8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 8.1. Introduction / Key Findings 8.2. Historical Market Size (US$ Million) Trends Analysis By Indication, 2017 to 2022 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 8.3.1. Asymptomatic CAUTI (Bacteriuria) 8.3.2. Symptomatic CAUTI (Bacteremic) 8.4. Market Attractiveness Analysis By Indication 9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 9.1. Introduction / Key Findings 9.2. Historical Market Size (US$ Million) Trends Analysis By Distribution Channel, 2017 to 2022 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 9.3.1. Hospital Pharmacies 9.3.2. Gynecology and Urology Clinics 9.3.3. Drug Stores 9.3.4. Retail Pharmacies 9.3.5. Online Drug Stores 9.4. Market Attractiveness Analysis By Distribution Channel 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region 10.1. Introduction 10.2. Historical Market Size (US$ Million) Trend Analysis By Region, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 10.3.1. North America 10.3.2. Latin America 10.3.3. Europe 10.3.4. East Asia 10.3.5. South Asia 10.3.6. Oceania 10.3.7. Middle East and Africa (MEA) 10.4. Market Attractiveness Analysis By Region 11. North America Analysis 2017 to 2022 and Forecast 2023 to 2033 11.1. Introduction 11.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022 Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. U.S. 11.2.1.2. Canada 11.2.2. By Drug Type 11.2.3. Indication 11.2.4. Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Type 11.3.3. Indication 11.3.4. Distribution Channel 11.4. Market Trends 11.5. Key Market Participants - Intensity Mapping 11.6. Drivers and Restraints - Impact Analysis 11.7. Country Level Analysis & Forecast 11.7.1. U.S. Market Analysis 11.7.1.1. Introduction 11.7.1.2. Market Analysis and Forecast By Market Taxonomy 11.7.1.2.1. By Drug Type 11.7.1.2.2. By Indication 11.7.1.2.3. By Distribution Channel 11.7.2. Canada Market Analysis 11.7.2.1. Introduction 11.7.2.2. Market Analysis and Forecast By Market Taxonomy 11.7.2.2.1. By Drug Type 11.7.2.2.2. By Indication 11.7.2.2.3. By Distribution Channel 12. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 12.1. Introduction 12.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 12.3.1. By Country 12.3.1.1. Mexico 12.3.1.2. Brazil 12.3.1.3. Argentina 12.3.1.4. Rest of Latin America 12.3.2. By Drug Type 12.3.3. By Indication 12.3.4. By Distribution Channel 12.4. Market Attractiveness Analysis 12.4.1. By Country 12.4.2. By Drug Type 12.4.3. By Indication 12.4.4. By Distribution Channel 12.5. Market Trends 12.6. Key Market Participants - Intensity Mapping 12.7. Drivers and Restraints - Impact Analysis 12.8. Country Level Analysis & Forecast 12.8.1. Mexico Market Analysis 12.8.1.1. Introduction 12.8.1.2. Market Analysis and Forecast By Market Taxonomy 12.8.1.2.1. By Drug Type 12.8.1.2.2. By Indication 12.8.1.2.3. By Distribution Channel 12.8.2. Brazil Market Analysis 12.8.2.1. Introduction 12.8.2.2. Market Analysis and Forecast By Market Taxonomy 12.8.2.2.1. By Drug Type 12.8.2.2.2. By Indication 12.8.2.2.3. By Distribution Channel 12.8.3. Argentina Market Analysis 12.8.3.1. Introduction 12.8.3.2. Market Analysis and Forecast By Market Taxonomy 12.8.3.2.1. By Drug Type 12.8.3.2.2. By Indication 12.8.3.2.3. By Distribution Channel 13. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 13.1. Introduction 13.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 13.3.1. By Country 13.3.1.1. Germany 13.3.1.2. Italy 13.3.1.3. France 13.3.1.4. U.K. 13.3.1.5. Spain 13.3.1.6. BENELUX 13.3.1.7. Russia 13.3.1.8. Rest of Europe 13.3.2. By Drug Type 13.3.3. By Indication 13.3.4. By Distribution Channel 13.4. Market Attractiveness Analysis 13.4.1. By Country 13.4.2. By Drug Type 13.4.3. By Indication 13.4.4. By Distribution Channel 13.5. Market Trends 13.6. Key Market Participants - Intensity Mapping 13.7. Drivers and Restraints - Impact Analysis 13.8. Country Level Analysis & Forecast 13.8.1. Germany Market Analysis 13.8.1.1. Introduction 13.8.1.2. Market Analysis and Forecast By Market Taxonomy 13.8.1.2.1. By Drug Type 13.8.1.2.2. By Indication 13.8.1.2.3. By Distribution Channel 13.8.2. Italy Market Analysis 13.8.2.1. Introduction 13.8.2.2. Market Analysis and Forecast By Market Taxonomy 13.8.2.2.1. By Drug Type 13.8.2.2.2. By Indication 13.8.2.2.3. By Distribution Channel 13.8.3. France Market Analysis 13.8.3.1. Introduction 13.8.3.2. Market Analysis and Forecast By Market Taxonomy 13.8.3.2.1. By Drug Type 13.8.3.2.2. By Indication 13.8.3.2.3. By Distribution Channel 13.8.4. U.K. Market Analysis 13.8.4.1. Introduction 13.8.4.2. Market Analysis and Forecast By Market Taxonomy 13.8.4.2.1. By Drug Type 13.8.4.2.2. By Indication 13.8.4.2.3. By Distribution Channel 13.8.5. Spain Market Analysis 13.8.5.1. Introduction 13.8.5.2. Market Analysis and Forecast By Market Taxonomy 13.8.5.2.1. By Drug Type 13.8.5.2.2. By Indication 13.8.5.2.3. By Distribution Channel 13.8.6. Russia Market Analysis 13.8.6.1. Introduction 13.8.6.2. Market Analysis and Forecast By Market Taxonomy 13.8.6.2.1. By Drug Type 13.8.6.2.2. By Indication 13.8.6.2.3. By Distribution Channel 13.8.7. BENELUX Market Analysis 13.8.7.1. Introduction 13.8.7.2. Market Analysis and Forecast By Market Taxonomy 13.8.7.2.1. By Drug Type 13.8.7.2.2. By Indication 13.8.7.2.3. By Distribution Channel 14. East Asia Analysis 2017 to 2022 and Forecast 2023 to 2033 14.1. Introduction 14.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 14.3.1. By Country 14.3.1.1. China 14.3.1.2. Japan 14.3.1.3. South Korea 14.3.2. By Drug Type 14.3.3. By Indication 14.3.4. By Distribution Channel 14.4. Market Attractiveness Analysis 14.4.1. By Country 14.4.2. By Drug Type 14.4.3. By Indication 14.4.4. By Distribution Channel 14.5. Market Trends 14.6. Key Market Participants - Intensity Mapping 14.7. Drivers and Restraints - Impact Analysis 14.8. Country Level Analysis & Forecast 14.8.1. China Market Analysis 14.8.1.1. Introduction 14.8.1.2. Market Analysis and Forecast By Market Taxonomy 14.8.1.2.1. By Drug Type 14.8.1.2.2. By Indication 14.8.1.2.3. By Distribution Channel 14.8.2. Japan Market Analysis 14.8.2.1. Introduction 14.8.2.2. Market Analysis and Forecast By Market Taxonomy 14.8.2.2.1. By Drug Type 14.8.2.2.2. By Indication 14.8.2.2.3. By Distribution Channel 14.8.3. South Korea Market Analysis 14.8.3.1. Introduction 14.8.3.2. Market Analysis and Forecast By Market Taxonomy 14.8.3.2.1. By Drug Type 14.8.3.2.2. By Indication 14.8.3.2.3. By Distribution Channel 15. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 15.1. Introduction 15.2. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 15.3.1. By Country 15.3.1.1. India 15.3.1.2. Indonesia 15.3.1.3. Malaysia 15.3.1.4. Thailand 15.3.1.5. Rest of South Asia 15.3.2. By Drug Type 15.3.3. By Indication 15.3.4. By Distribution Channel 15.4. Market Attractiveness Analysis 15.4.1. By Country 15.4.2. By Drug Type 15.4.3. By Indication 15.4.4. By Distribution Channel 15.5. Market Trends 15.6. Key Market Participants - Intensity Mapping 15.7. Drivers and Restraints - Impact Analysis 15.8. Country Level Analysis & Forecast 15.8.1. India Market Analysis 15.8.1.1. Introduction 15.8.1.2. Market Analysis and Forecast By Market Taxonomy 15.8.1.2.1. By Drug Type 15.8.1.2.2. By Indication 15.8.1.2.3. By Distribution Channel 15.8.2. Indonesia Market Analysis 15.8.2.1. Introduction 15.8.2.2. Market Analysis and Forecast By Market Taxonomy 15.8.2.2.1. By Drug Type 15.8.2.2.2. By Indication 15.8.2.2.3. By Distribution Channel 15.8.3. Malaysia Market Analysis 15.8.3.1. Introduction 15.8.3.2. Market Analysis and Forecast By Market Taxonomy 15.8.3.2.1. By Drug Type 15.8.3.2.2. By Indication 15.8.3.2.3. By Distribution Channel 15.8.4. Thailand Market Analysis 15.8.4.1. Introduction 15.8.4.2. Market Analysis and Forecast By Market Taxonomy 15.8.4.2.1. By Drug Type 15.8.4.2.2. By Indication 15.8.4.2.3. By Distribution Channel 16. Oceania Market 2017 to 2022 and Forecast 2023-2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) Trends Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. Australia 16.3.1.2. New Zealand 16.3.2. By Drug Type 16.3.3. By Indication 16.3.4. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Type 16.4.3. By Indication 16.4.4. By Distribution Channel 16.5. Market Trends 16.6. Key Market Participants - Intensity Mapping 16.7. Drivers and Restraints - Impact Analysis 16.8. Country Level Analysis & Forecast 16.8.1. Australia Market Analysis 16.8.1.1. Introduction 16.8.1.2. Market Analysis and Forecast By Market Taxonomy 16.8.1.2.1. By Drug Type 16.8.1.2.2. By Indication 16.8.1.2.3. By Distribution Channel 16.8.2. New Zealand Market Analysis 16.8.2.1. Introduction 16.8.2.2. Market Analysis and Forecast By Market Taxonomy 16.8.2.2.1. By Drug Type 16.8.2.2.2. By Indication 16.8.2.2.3. By Distribution Channel 17. Middle East and Africa (MEA) Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Pricing Analysis 17.3. Historical Market Size (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022 17.4. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.4.1. By Country 17.4.1.1. GCC Countries 17.4.1.2. Türkiye 17.4.1.3. Northern Africa 17.4.1.4. South Africa 17.4.1.5. Rest of Middle East and Africa 17.4.2. By Drug Type 17.4.3. By Indication 17.4.4. By Distribution Channel 17.5. Market Attractiveness Analysis 17.5.1. By Country 17.5.2. By Drug Type 17.5.3. By Indication 17.5.4. By Distribution Channel 17.6. Market Trends 17.7. Key Market Participants - Intensity Mapping 17.8. Drivers and Restraints - Impact Analysis 17.9. Country Level Analysis & Forecast 17.9.1. GCC Countries Market Analysis 17.9.1.1. Introduction 17.9.1.2. Market Analysis and Forecast By Market Taxonomy 17.9.1.2.1. By Drug Type 17.9.1.2.2. By Indication 17.9.1.2.3. By Distribution Channel 17.9.2. Türkiye Market Analysis 17.9.2.1. Introduction 17.9.2.2. Market Analysis and Forecast By Market Taxonomy 17.9.2.2.1. By Drug Type 17.9.2.2.2. By Indication 17.9.2.2.3. By Distribution Channel 17.9.3. Northern Africa Market Analysis 17.9.3.1. Introduction 17.9.3.2. Market Analysis and Forecast By Market Taxonomy 17.9.3.2.1. By Drug Type 17.9.3.2.2. By Indication 17.9.3.2.3. By Distribution Channel 17.9.4. South Africa Market Analysis 17.9.4.1. Introduction 17.9.4.2. Market Analysis and Forecast By Market Taxonomy 17.9.4.2.1. By Drug Type 17.9.4.2.2. By Indication 17.9.4.2.3. By Distribution Channel 18. Market Structure Analysis 18.1. Market Analysis By Tier of Companies 18.2. Market Share Analysis of Top Players 18.3. Market Concentration 18.4. Market Presence Analysis 18.4.1. Regional Footprint Analysis 18.4.2. Product Footprint Analysis 18.4.3. Channel Footprint Analysis 19. Competition Analysis 19.1. Competition Dashboard 19.2. Branding and Promotional Strategies, By Key Players 19.3. Key Development Analysis 19.4. Competition Deep Dive 19.4.1. Pfizer 19.4.1.1. Overview 19.4.1.2. Product Portfolio 19.4.1.3. Sales Footprint 19.4.1.4. Key Developments 19.4.1.5. SWOT Analysis 19.4.1.6. Strategy Overview 19.4.1.6.1. Marketing Strategies 19.4.1.6.2. Product Strategies 19.4.1.6.3. Channel Strategies 19.4.2. Merck & Co., Inc. 19.4.2.1. Overview 19.4.2.2. Product Portfolio 19.4.2.3. Sales Footprint 19.4.2.4. Key Developments 19.4.2.5. SWOT Analysis 19.4.2.6. Strategy Overview 19.4.2.6.1. Marketing Strategies 19.4.2.6.2. Product Strategies 19.4.2.6.3. Channel Strategies 19.4.3. GlaxoSmithKline (GSK) 19.4.3.1. Overview 19.4.3.2. Product Portfolio 19.4.3.3. Sales Footprint 19.4.3.4. Key Developments 19.4.3.5. SWOT Analysis 19.4.3.6. Strategy Overview 19.4.3.6.1. Marketing Strategies 19.4.3.6.2. Product Strategies 19.4.3.6.3. Channel Strategies 19.4.4. AstraZeneca 19.4.4.1. Overview 19.4.4.2. Product Portfolio 19.4.4.3. Sales Footprint 19.4.4.4. Key Developments 19.4.4.5. SWOT Analysis 19.4.4.6. Strategy Overview 19.4.4.6.1. Marketing Strategies 19.4.4.6.2. Product Strategies 19.4.4.6.3. Channel Strategies 19.4.5. Bayer AG 19.4.5.1. Overview 19.4.5.2. Product Portfolio 19.4.5.3. Sales Footprint 19.4.5.4. Key Developments 19.4.5.5. SWOT Analysis 19.4.5.6. Strategy Overview 19.4.5.6.1. Marketing Strategies 19.4.5.6.2. Product Strategies 19.4.5.6.3. Channel Strategies 19.4.6. Johnson & Johnson 19.4.6.1. Overview 19.4.6.2. Product Portfolio 19.4.6.3. Sales Footprint 19.4.6.4. Key Developments 19.4.6.5. SWOT Analysis 19.4.6.6. Strategy Overview 19.4.6.6.1. Marketing Strategies 19.4.6.6.2. Product Strategies 19.4.6.6.3. Channel Strategies 19.4.7. Novartis International AG 19.4.7.1. Overview 19.4.7.2. Product Portfolio 19.4.7.3. Sales Footprint 19.4.7.4. Key Developments 19.4.7.5. SWOT Analysis 19.4.7.6. Strategy Overview 19.4.7.6.1. Marketing Strategies 19.4.7.6.2. Product Strategies 19.4.7.6.3. Channel Strategies 19.4.8. Sanofi 19.4.8.1. Overview 19.4.8.2. Product Portfolio 19.4.8.3. Sales Footprint 19.4.8.4. Key Developments 19.4.8.5. SWOT Analysis 19.4.8.6. Strategy Overview 19.4.8.6.1. Marketing Strategies 19.4.8.6.2. Product Strategies 19.4.8.6.3. Channel Strategies 19.4.9. Roche Holding AG 19.4.9.1. Overview 19.4.9.2. Product Portfolio 19.4.9.3. Sales Footprint 19.4.9.4. Key Developments 19.4.9.5. SWOT Analysis 19.4.9.6. Strategy Overview 19.4.9.6.1. Marketing Strategies 19.4.9.6.2. Product Strategies 19.4.9.6.3. Channel Strategies 19.4.10. Eli Lilly and Company 19.4.10.1. Overview 19.4.10.2. Product Portfolio 19.4.10.3. Sales Footprint 19.4.10.4. Key Developments 19.4.10.5. SWOT Analysis 19.4.10.6. Strategy Overview 19.4.10.6.1. Marketing Strategies 19.4.10.6.2. Product Strategies 19.4.10.6.3. Channel Strategies 19.4.11. Bristol-Myers Squibb Company 19.4.11.1. Overview 19.4.11.2. Product Portfolio 19.4.11.3. Sales Footprint 19.4.11.4. Key Developments 19.4.11.5. SWOT Analysis 19.4.11.6. Strategy Overview 19.4.11.6.1. Marketing Strategies 19.4.11.6.2. Product Strategies 19.4.11.6.3. Channel Strategies 19.4.12. Abbott Laboratories 19.4.12.1. Overview 19.4.12.2. Product Portfolio 19.4.12.3. Sales Footprint 19.4.12.4. Key Developments 19.4.12.5. SWOT Analysis 19.4.12.6. Strategy Overview 19.4.12.6.1. Marketing Strategies 19.4.12.6.2. Product Strategies 19.4.12.6.3. Channel Strategies 19.4.13. Astellas Pharma Inc. 19.4.13.1. Overview 19.4.13.2. Product Portfolio 19.4.13.3. Sales Footprint 19.4.13.4. Key Developments 19.4.13.5. SWOT Analysis 19.4.13.6. Strategy Overview 19.4.13.6.1. Marketing Strategies 19.4.13.6.2. Product Strategies 19.4.13.6.3. Channel Strategies 19.4.14. Boehringer Ingelheim 19.4.14.1. Overview 19.4.14.2. Product Portfolio 19.4.14.3. Sales Footprint 19.4.14.4. Key Developments 19.4.14.5. SWOT Analysis 19.4.14.6. Strategy Overview 19.4.14.6.1. Marketing Strategies 19.4.14.6.2. Product Strategies 19.4.14.6.3. Channel Strategies 19.4.15. Daiichi Sankyo Company, Limited 19.4.15.1. Overview 19.4.15.2. Product Portfolio 19.4.15.3. Sales Footprint 19.4.15.4. Key Developments 19.4.15.5. SWOT Analysis 19.4.15.6. Strategy Overview 19.4.15.6.1. Marketing Strategies 19.4.15.6.2. Product Strategies 19.4.15.6.3. Channel Strategies 19.4.16. Gilead Sciences, Inc. 19.4.16.1. Overview 19.4.16.2. Product Portfolio 19.4.16.3. Sales Footprint 19.4.16.4. Key Developments 19.4.16.5. SWOT Analysis 19.4.16.6. Strategy Overview 19.4.16.6.1. Marketing Strategies 19.4.16.6.2. Product Strategies 19.4.16.6.3. Channel Strategies 19.4.17. Mylan N.V. 19.4.17.1. Overview 19.4.17.2. Product Portfolio 19.4.17.3. Sales Footprint 19.4.17.4. Key Developments 19.4.17.5. SWOT Analysis 19.4.17.6. Strategy Overview 19.4.17.6.1. Marketing Strategies 19.4.17.6.2. Product Strategies 19.4.17.6.3. Channel Strategies 19.4.18. Teva Pharmaceutical Industries Ltd. 19.4.18.1. Overview 19.4.18.2. Product Portfolio 19.4.18.3. Sales Footprint 19.4.18.4. Key Developments 19.4.18.5. SWOT Analysis 19.4.18.6. Strategy Overview 19.4.18.6.1. Marketing Strategies 19.4.18.6.2. Product Strategies 19.4.18.6.3. Channel Strategies 19.4.19. Sun Pharmaceutical Industries Ltd. 19.4.19.1. Overview 19.4.19.2. Product Portfolio 19.4.19.3. Sales Footprint 19.4.19.4. Key Developments 19.4.19.5. SWOT Analysis 19.4.19.6. Strategy Overview 19.4.19.6.1. Marketing Strategies 19.4.19.6.2. Product Strategies 19.4.19.6.3. Channel Strategies 19.4.20. Lupin Limited 19.4.20.1. Overview 19.4.20.2. Product Portfolio 19.4.20.3. Sales Footprint 19.4.20.4. Key Developments 19.4.20.5. SWOT Analysis 19.4.20.6. Strategy Overview 19.4.20.6.1. Marketing Strategies 19.4.20.6.2. Product Strategies 19.4.20.6.3. Channel Strategies 20. Assumptions and Acronyms Used 21. Research Methodology
Healthcare
June 2019
REP-GB-2533
March 2024
195 pages
Healthcare
June 2019
REP-GB-1340
January 2024
218 pages
Explore Healthcare Insights
View Reports